🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cambridge
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Cambridge

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 33 Manchester 11 Cambridge 10 Edinburgh 7 Plymouth 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca64 Merck Sharp & Dohme LLC26 Hoffmann-La Roche15 Janssen Research & Development, LLC15 AbbVie13 Clear sponsor filter
Site city
London33 Manchester11 Cambridge10 Edinburgh7 Plymouth7
All 62 cities
Target enrolment
to
10 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants
NCT07789899Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 1
24
Cambridge
2026-08-18
Recruiting
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
NCT07438782Neoplasms
GlaxoSmithKline
Phase 1
97
Cambridge
2026-03-23
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
GlaxoSmithKline
Phase 3
450
Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield
2025-12-03
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
Cambridge, Exeter, London, Newcastle upon Tyne
2024-12-11
Active, closed
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
NCT06681181Colitis, Ulcerative
GlaxoSmithKline
Phase 1
48
Cambridge
2024-11-18
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
GlaxoSmithKline
Phase 2
393
Bristol, Cambridge, Glasgow Strathclyde, Leeds West Yorkshire, Liverpool, London, Middlesbrough, Plymouth
2024-09-27
Recruiting
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
NCT06576271Systemic Lupus Erythematosus
GlaxoSmithKline
Phase 1
142
Cambridge, Liverpool, London, Middlesex
2024-09-02
Recruiting
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
NCT06431594Solid Tumors, Neoplasms
GlaxoSmithKline
Phase 1
675
Cambridge, London
2024-07-02
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 1
127
Barnsley, Blackpool, Cambridge, Cannock, London, Manchester, West Yorkshire
2023-11-27
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
GlaxoSmithKline
Phase 3
163
Birmingham, Cambridge, London
2022-07-14
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/cambridge

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.